Analysis and Critique of Delaware HB 422

This post was written by Perplexity, reviewed by Dr. Varipapa and posted on May 15, 2026

HB 422 would create a new Delaware Title 16 chapter requiring enhanced informed consent before vaccines are administered to infants under 12 months at well-child visits, plus mandatory documentation of recent vaccination history in every SUID/SIDS investigation. The bill was introduced May 14, 2026, assigned to the House Health & Human Development Committee, and currently has an incomplete fiscal note.

Bottom line

The strongest part of the bill is its call for better documentation in infant death investigations, because complete vaccination history is a legitimate data point in any thorough SUID review.

The weakest part is that the informed-consent language appears to elevate a temporal association between the 2-to-4-month vaccine schedule and peak SIDS age into a legally mandated warning, even though CDC says multiple studies and safety reviews have found that vaccines do not cause and are not linked to SIDS.

What the bill would do

• Enhanced consent before infant vaccination: Providers would have to discuss the benefits and side effects of each vaccine, the fact that SIDS/SUID peaks at 2 to 4 months, the possibility that unexplained deaths in that window may be classified as SIDS even if they occur shortly after vaccination, VAERS reporting, and VICP claims.
• Signed acknowledgment form: DHSS would have to create a standardized one-page plain-language form, and providers administering infant vaccines would have to use it.
• Licensing-board enforcement: Noncompliance would not create a standalone damages claim, but it could be considered by medical or other licensing boards in disciplinary proceedings.
• SUID investigation documentation: Medical examiners or investigating authorities would have to document vaccine dates, types, and manufacturers for vaccines administered in the 30 days before death, include that information in the autopsy report, and forward it to the Child Death Review Commission.

Strengths

• Transparency: The bill addresses a real trust problem by ensuring parents are told how to report suspected adverse events to VAERS and how to seek compensation through VICP. VICP is a federal no-fault alternative to traditional tort litigation for people found to have been injured by certain vaccines.
• Better records: Requiring complete recent vaccine history in SUID investigations is defensible as a forensic documentation rule, especially because SUID includes deaths in infants under 1 year with no immediately obvious cause, including SIDS, unknown cause, and accidental suffocation or strangulation in bed.
• No direct vaccine restriction: The bill does not ban, delay, or condition access to recommended vaccines beyond an additional discussion and signed acknowledgment.

Weaknesses and risks

• Scientific framing risk: The bill’s required discussion emphasizes that SIDS/SUID peaks at 2 to 4 months and that deaths may occur shortly after vaccination, but CDC describes that timing overlap as a reason some people question a link while concluding that studies have found vaccines do not cause and are not linked to SIDS. A 2007 meta-analysis found immunizations were associated with a lower adjusted risk of SIDS, with a summary odds ratio of 0.54, while noting that the healthy-vaccinee effect may be important.
• Potential to increase hesitancy: The bill could unintentionally make routine infant vaccination feel unusually dangerous by requiring a SIDS-focused signed form for infants under 12 months. CDC warns that VAERS data can be misunderstood because reports alone do not show causation and increased reporting can create a false impression that vaccines are dangerous.
• Duplicative consent burden: Federal law already requires all public and private vaccine providers to give the appropriate Vaccine Information Statement before every dose of covered vaccines, including each dose in a multi-dose series. Delaware can require more than the federal floor, but the policy question is whether a separate signed SIDS-focused acknowledgment improves informed consent enough to justify workflow burden and possible deterrence.
• Forensic bias concern: The clause saying that if death occurs within the “7-day post vaccine time frame,” the medical examiner “shall consider a vaccine reaction as a cause of death and work to prove or disprove” is the bill’s most problematic drafting choice. A better formulation would require neutral assessment of all plausible causes and contributing factors, including recent vaccination history, without singling out one hypothesis for proof or disproof.
• Legal ambiguity: The bill says noncompliance does not create a separate damages cause of action, but it does not clearly say whether noncompliance could be used as evidence in malpractice or negligence litigation. If lawmakers intend to avoid civil-liability spillover, they should say so directly.
• Drafting problems: The chapter title says “Document Information” rather than “Documentation,” and § 803E says “If death occurs with the 7-day post vaccine time frame,” which appears to mean “within”. Those errors matter because they will be read by providers, agencies, courts, and families in emotionally charged settings.

Suggested amendments

• Neutralize the consent language: Require disclosure that SIDS peaks at 2 to 4 months and that this overlaps with routine vaccination visits, but add that current CDC-reviewed evidence does not show vaccines cause or are linked to SIDS.
• Separate education from alarm: Require providers to give parents VAERS and VICP information, but include a plain-language explanation that VAERS is an early-warning surveillance system and that a VAERS report alone does not prove a vaccine caused an event.
• Revise the death-investigation standard: Replace “shall consider a vaccine reaction as a cause of death and work to prove or disprove” with language requiring investigators to document recent vaccination and evaluate it alongside sleep environment, infection, congenital conditions, toxicology, and other medically relevant factors.
• Clarify civil effect: Add whether violation of the statute is inadmissible in civil litigation, merely non-dispositive, or available only for licensing review.
• Add implementation details: Specify who must store the signed form, how long it must be retained, whether electronic signatures qualify, whether telehealth pre-counseling counts, and whether emergency or inpatient vaccination scenarios are excluded.